Table 1: Baseline Characteristics.
| Characteristic | Total cohort, n = 50 |
| Age, years [mean (SD)] | 57 (10) |
| Males, n (%) | 39 (78%) |
| Black/African American, n (%) | 42 (84%) |
| Caucasians, n (%) | 4 (8%) |
| Hispanic, n (%) | 4 (8%) |
| Genotype, n (%) | |
| 1 | 43 (86%) |
| 1a | 30 (60%) |
| 1b | 13 (26%) |
| 2 | 3 (6%) |
| 3 | 3 (6%) |
| 4 | 1 (2%) |
| Advanced fibrosis/cirrhosis (F3-4), n (%) | 28 (56%) |
| Baseline HCV RNA (IU/ml), median (range) | 2,769,930 (33,270-16,400,000) |
| HCV RNA > 800,000 (IU/ml), n (%) | 39 (78%) |
| DAA Therapy | |
| SOF/LDV | 31 (62%) |
| EBR/GZR | 8 (16%) |
| SOF/VEL | 7 (14%) |
| OBV/PTV/r + DSV +/- RBV | 4 (8%) |
| Previous HCV treatment status | |
| Naïve, n (%) | 47 (94%) |
| Experienced, n (%) [pegIFN + RBV] | 3 (6%) |
| History of prior heroin use | 3 (6%) |
| HIV co-infection, n (%) | 33 (66%) |
| CD4+ cell count (cells/mm3), median (range) | 588 (95-2200) |
| HIV-1 RNA < 50 copies/ml, n (%) | 28/33 (85%) |
| Receiving HAART, n (%) | 32/33 (97%) |
| Payer, n (%) | |
| Medicare | 19 (38%) |
| Medicaid | 8 (16%) |
| Private insurance | 10 (20%) |
| Pharmaceutical Patient Assistance Program | 13 (26%) |
DAA: Direct acting antiviral therapy; DSV: Dasabuvir; EBR/GZR: Elbasvir/grazoprevir; HCV: Hepatitis C virus; HAART: Highly active antiretroviral therapy; HIV: Human immunodeficiency virus; OBV/PTV/r: Ombitasvir/paritaprevir/ritonavir; pegIFN: Pegylated interferon; RBV: Ribavirin; SOF/LDV: Sofosbuvir/ledipasvir; SOF/VEL: Sofosbuvir/velpatasvir.